Summary
Eli Lilly's weight-loss drug, tirzepatide, led to fewer nighttime incidents. The company plans to ask global regulators to approve tirzapatide for this use in the middle of this year. During the fourth quarter, Lilly earned an adjusted $2.49 per share on $9.35 billion in sales. Sales climbed 28% to top forecasts for $8.95 billion. After the fourth-quarter report, Eli Lilly guided to $40.4 billion to $41.6 billion in 2024 sales. The company expects demand for its GLP-1 drugs to "outpace supply" Biogen's Leqembi gained full approval for Alzheimer's treatment based on its ability to remove amyloid. The FDA just said it plans to hold an advisory committee meeting to discuss the effectiveness and safety of donanemab. In August, Novo Nordisk said its obesity drug Wegovy cut the risk of cardiovascular events. Novo sells semaglutide as diabetes treatments known as Ozempic and Rybelsus. In this week's edition of The Daily Discussion, we look at some of the biggest issues of the day. This week's topic is the state of the economy. Today's Daily Discussion is about the state and economy.